MedTrace Logo

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

NCT05577819 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 515

Last updated 2024-12-09

No results posted yet for this study

Summary

Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.

Conditions

  • Transthyretin Amyloidosis
  • Heart Failure
  • Heart Failure, Diastolic
  • Amyloidosis

Interventions

DIAGNOSTIC_TEST

99mTc-pyrophosphate Scintigraphy

Cardiac Imaging Technique used to diagnose Transthyretin Cardiac Amyloidosis by use of 15 mCi of 99mTC-Pyrophosphate tracer

Sponsors & Collaborators

  • Akcea Therapeutics

    collaborator INDUSTRY

  • Pfizer

    collaborator INDUSTRY

  • Alnylam Pharmaceuticals

    collaborator INDUSTRY

  • Eidos Therapeutics, a BridgeBio company

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Hanna K Gaggin, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-02
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05577819 on ClinicalTrials.gov